Applied Spectral Imaging (ASI) new software release combines integrated workflows with advanced computer-aided capabilities
CARLSBAD, CA, April 8, 2025 – Applied Spectral Imaging (ASI), a global provider of biomedical imaging solutions, has launched GenASIs version 8.4.1 to offer integrated workflows combined with advanced computer-aided capabilities for both cytogenetics and pathology laboratories.
While precision medicine plays a growing role in guiding clinical decisions, diagnostic laboratories are under rising pressure to manage a constantly increasing workload while dealing with a reduction in qualified personnel. By embracing digital implementation, labs can optimize their processes, but this often requires profound changes in existing equipment and procedures.
“Combining advanced computer-aided workflows with scanner agnostic capabilities, ASI’s GenASIs version 8.4.1 provides a cost-effective and sustainable path to digital implementation” says Limor Shiposh, CEO of ASI. “By cutting in half the time needed to prepare G-banded or Q-banded karyograms, ASI’s new software version enables cytogenetics labs to manage their workload more efficiently, freeing up precious time for higher-value tasks. And the ability to seamlessly align H&E or IHC whole slide images from third-party scanners with FISH slides scanned on the ASI system enhances efficiency and accuracy of pathology labs” Limor added.
With its new software version, ASI supports laboratories in their journey to embrace digital implementation more efficiently. The option to combine digital pathology and cytogenetics workflows in the “All-in-One” platform further unifies critical processes while reducing cost, instrumentation footprint and training efforts. In addition, ASI’s AnyWhere solution enables global collaboration while ensuring the lab data is secure and compliant with regulatory standards. Compatible with both Windows 10 and Windows 11 operating systems, GenASIs v8.4.1 supports laboratories in their effort to comply with growing technological constraints.
The new update has been incorporated into ASI’s Brightfield, Fluorescence and Spectral imaging and analysis solutions including HiBand, HiFISH, CytoPower, HiPath Pro and PathFusion.
About Applied Spectral Imaging (ASI)
ASI is a global leader in biomedical imaging with a comprehensive product portfolio for karyotyping, H&E, IHC and Fluorescent In Situ Hybridization (FISH) imaging and analysis. ASI’s product portfolio is FDA-cleared for BandView Karyotyping, FISHView, SpotScan for CEP XY, UroVysion, ALK and HER2/neu FISH, and HiPath IHC Family for HER2, ER, PR and Ki67 in manual configuration. The ASI product family is IVDR compliant. Founded in 1993, ASI develops, markets, services and supports its products in more than 80 countries.
For more information about ASI, please visit www.spectral-imaging.com or e-mail sales@spectral-imaging.com
SOURCE: Applied Spectral Imaging
